Altimmune (ALT) CBO logs RSU-to-share conversion and tax share surrender

Rhea-AI Filing Summary

Altimmune, Inc.’s Chief Business Officer, Raymond M. Jordt, reported routine equity compensation activity. On January 27, 2026, 15,850 Restricted Stock Units (RSUs) were converted into an equal number of common shares at $0 per share. A separate transaction shows 4,229 common shares were surrendered at $6.18 per share to Altimmune solely to cover taxes associated with the RSU vesting. Following these transactions, Jordt directly owns 65,536 shares of common stock and 47,550 RSUs, which each represent a contingent right to receive one common share. The RSUs vest in substantially equal annual installments over four years following January 27, 2025, subject to continued service, and have no expiration date.

Insider Trade Summary

15,850 shares exercised/converted

Mixed 3 txns

Insider Jordt Raymond M

Role Chief Business Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	15,850	$0.00	--
Exercise	Common Stock, par value $0.0001	15,850	$0.00	--
Tax Withholding	Common Stock, par value $0.0001	4,229	$6.18	$26K

Holdings After Transaction: Restricted Stock Units — 47,550 shares (Direct); Common Stock, par value $0.0001 — 69,765 shares (Direct)

Footnotes (1)

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jordt Raymond M

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	01/27/2026		M		15,850	A	$0(1)	69,765	D
Common Stock, par value $0.0001	01/27/2026		F(2)		4,229	D	$6.18	65,536	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/27/2026		M			15,850	(3)	(3)	Common Stock, par value $0.0001	15,850	$0	47,550	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

2. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

3. The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

	/s/ Gregory Weaver, as Attorney-in-Fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Altimmune (ALT) report for Raymond M. Jordt?

Altimmune reported that Chief Business Officer Raymond M. Jordt had 15,850 Restricted Stock Units convert into common shares on January 27, 2026. In a related tax-withholding transaction, 4,229 common shares were surrendered back to Altimmune at $6.18 per share.

How many Altimmune (ALT) shares does Raymond M. Jordt own after this Form 4?

After the reported transactions, Raymond M. Jordt directly owns 65,536 shares of Altimmune common stock. He also holds 47,550 Restricted Stock Units, each representing a contingent right to receive one additional share of common stock when the units vest.

What are the terms of the Restricted Stock Units reported by Altimmune (ALT)?

Each Restricted Stock Unit represents a contingent right to receive one share of Altimmune common stock when vested. The RSUs vest in substantially equal annual installments over four years following January 27, 2025, contingent on Jordt’s continued service, and they have no expiration date.

Why were 4,229 Altimmune (ALT) shares surrendered in this Form 4 filing?

The 4,229 Altimmune common shares were surrendered to the company solely to cover taxes due upon the vesting of Restricted Stock Units. This type of transaction is labeled with code “F” and is a common tax-withholding mechanism for equity compensation.

What does transaction code “M” mean in the Altimmune (ALT) Form 4?

Transaction code “M” in this Form 4 indicates the exercise or conversion of derivative securities, here Restricted Stock Units, into common stock. On January 27, 2026, 15,850 RSUs were converted into 15,850 Altimmune common shares at a price of $0 per share.